Accession Therapeutics Limited

Name: Accession Therapeutics Limited
Address: Church Lane, Bristol, England, United Kingdom, BS16 1, Bristol
Telephone: '+44 78 8078 7185

Bristolbiotechnology

About

Accession Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom. Founded in December 2020, the company focuses on developing innovative immuno-oncology therapeutics aimed at treating solid cancers. Its proprietary platform, Trocept, utilizes stealth virus technology to deliver targeted cancer immunotherapies, allowing for the precise targeting of tumor cells while sparing healthy cells. The company's lead program, TROCEPT-01 (ATTR-01), is currently in Phase 1 clinical development, with patient recruitment underway in the ATTEST trial. Additionally, Accession Therapeutics is developing a second candidate, TROCEPT-02 (ATTR-02), as part of its expanding pipeline. The company has successfully raised significant funding to support its operations and clinical trials, and it is actively pursuing partnerships for further development in the field of cancer treatment.